Mumbai: Supriya Lifescience Ltd., a global pharmaceutical industry leader, achieved two significant milestones, strengthening its position in international markets. The company has acquired approval from Brazil’s health authority, ANVISA (Agência Nacional de Vigilância Sanitária), for Esketamine Hydrochloride, which is a major step in growing its product range in Brazil and the rest of LATAM. Supriya Lifescience is the first firm in Brazil to have received regulatory permission for this highly specialized pharmaceutical.
Esketamine hydrochloride is a vital drug to be used for treating mental illness and is likely to significantly impact the LATAM market. This approval will enable the company to provide state-of-the-art, high-quality healthcare solutions in a market where demand for novel, reasonably priced drugs is growing.
Highlights
- Supriya Lifescience becomes the first Indian company to receive nod for Esketamine Hydrochloride from Brazil’s health authority ANVISA.
- Supriya Lifescience have developed groundbreaking technique for low-cost manufacturing of Atorvastatin, which is worldwide used for a key treatment for controlling cholesterol and preventing cardiovascular disease.
Moreover, the business submitted a ground-breaking patent application for an enhanced, low-cost method of atorvastatin synthesis. This ground-breaking technique makes drugs more affordable for patients by increasing their efficacy while reducing production costs. Global healthcare relies heavily on atorvastatin, a key treatment for controlling cholesterol and preventing cardiovascular disease, and this achievement shows Supriya’s dedication to drug cost and raising accessibility.
Dr. Satish Wagh, Executive Chairman and Whole Time Director, Supriya Lifescience Ltd. stated, “Our commitment to transforming pharmaceutical manufacturing while maintaining affordability is demonstrated by our invention in the synthesis of atorvastatin. Our global presence is strengthened by the CADIFA approval, which also allows us to introduce cutting-edge therapies like Esketamine Hydrochloride in important foreign countries, starting with Brazil.”
With CADIFA approval in place, Supriya Lifescience is now ready to tap into the fast- growing LATAM market. The company’s continued focus on innovation, regulatory compliance, and its mission to make high-quality healthcare accessible globally positions it as a key player in the international pharmaceutical landscape.
